Takahashi M, Kawai K, Asai N. Role of the RET proto-oncogene in cancer and development. Journal of the Japan Meteorological Agency. 2020;3(3):175–81.
Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, and others. Summary of FDA Approval: Serpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clinical Cancer Institute 2021;27(8):2130–5.
Accardo G, Conzo G, Esposito D, Gambardella C, Masella M, Castaldo F, et al. The genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41(Supplement 1):S2–6.
Elisei R, Molinaro E, Agat L, Bottici V, Viola D, Biagini A, and others. Ret oncogene and thyroid cancer. Journal of Inherited Syndromes and Gene Therapy. 2014; 5:1.
Clampitz from GW, Norton from JA. His RET gene mutations (genotype and phenotype) with multiple endocrine neoplasia type 2 and familial medullary thyroid cancer. cancer. 2014;120(13):1920–31.
Virus LJ, Sherman E, Robinson B, Solomon B, Kang H, Roach J, et al. Efficacy of selpercatinib in RET degenerative thyroid cancer. N English J Med 2020;383(9):825–35.
Takeuchi K. The discovery story of RET fusions in lung cancer: a mini-review. front physical. 2019; 10:216.
Drusboski LM, Rodriguez E, Dawar R, Ikpeas CV. Treatment strategies in RET gene-rearranged non-small cell lung cancer. J Hematol Onkol. 2021;14(1):50.
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, et al. In routine practice and clinical research he ESMO recommendations on standard methods for detecting RET fusions and mutations. Ann Ongol. 2021;32(3):337–50.
Tunisen E, Weinand B, Udovic-Gagra D, Vrcic L, Szolkowska M, Hoffmann P, and others. Lung cancer biomarker testing: a European perspective. Transl Lung Cancer Institute 2020;9(3):887–97.
Ferrara R, Auger N, Auclin E, Besse B. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Sorak Ongol. 2018;13(1):27–45.
Herbst RS, Eisner DL, Sonnett JR, Turk AT, Weintraub JL, Lindemann NI. Practical considerations for routine clinical biomarker testing in non-small cell lung cancer: focus on testing for RET fusions. Front Med (Lausanne). 2020;7:562480.
Reale ML, Bertaglia V, Listì A, Novelo S, Pasiglia F. Molecular testing and therapeutic strategies in patients with RET-rearranged NSCLC: Look ahead with your goals in mind. Journal of Molecular Pathology. 2022;3(1):24–37.
Herbst RS, Eisner DL, Sonnett JR, Turk AT, Weintraub JL, Lindemann NI. Practical considerations for routine clinical biomarker testing in non-small cell lung cancer: focus on testing for RET fusions. front med. 2021; 7:562480.
Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M. The role of the pathologist in the next generation era of tumor molecular characterization. diagnose. 2021; 11(2):339.
Ghofrani M, Ocal IT. Medullary thyroid cancer. Pathology case review. 2015;20(5):204–9.
Lindemann NI, Kegl PT, Eisner DL, Arcilla ME, Beasley MB, Vernicker EH, and others. Current Molecular Testing Guidelines for Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guidelines from the American Association of Pathologists, International Association for Lung Cancer Research, and Society for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–46.
Pisapia P, Limperio V, Galuppini F, Sajadi E, Russo A, Cerbelli B, and others. The evolving anatomic pathology landscape. Critical Lev Oncor Hematol. 2022; 178:103776.
Ebi H, Bando H. Precision Oncology and the Japanese Universal Health Coverage System. JCO Precision Cor. 2019;3:PO.19.00291.
Greg JP, Lee T, Kentucky Yoneda. Molecular testing strategies in non-small cell lung cancer: optimization of the diagnostic process. Transl Lung Cancer Institute 2019;8(3):286–301.
Imyanitov EN, Yekhleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: status and prospects. Critical Lev Oncor Hematol. 2021; 157:103194.
Jun Kikuchi, Yasushi Ohara, Kazuto Takada, Hiroshi Tanabe, Kazu Hatanaka, Satoshi Amano, et al. 2021;51(5):753–61.
Oczko-Wojciechowska M, Czarniecka A, Gawlik T, Jarzab B, Krajewska J. Current state of prognostic molecular markers in medullary thyroid cancer. end roll connect. 2020;9(12):R251–63.
Romay C, Tasit A, Molinaro E, Agat L, Bottic V, Viola D, and others. Lessons learned from 20 years: What impact will the RET genetic screening test have on the clinical management of medullary thyroid cancer? Cline endocrinol (Oxf). 2015;82(6):892–9.
Ngo HTT, Nguyen TPX, Vu TH, Jung CK, Hassell L, Kakudo K et al. Impact of molecular testing on the management of atypical thyroid nodules in western and Asian countries: a systematic review and meta-analysis. Endok Pasol. 2021;32(2):269–79.
Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, and others. Challenges of molecular testing in patients with advanced non-small cell lung cancer. lancet. 2016;388(10048):1002–11.
Matter MS, Chijioke O, Savic S, Bubendorf L. A review of the molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung cancer. Transl Lung Cancer Institute 2020;9(6):2645–55.
Sung S, Heymann JJ, Crapanzano JP, Moreira AL, Shu C, Bulman WA, et al. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. J Am Soc Site Patrol. 2020;9(5):332–45.
Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X. Thyroid cancer: phenotypic features, underlying biology, and potential relevance to targeted therapy. Int J Mol Sci. 2021;22(4):1950.
Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, Insurance coverage policies for pharmacogenomic and multigene testing in other cancers. J Pers Med. 2018;8(2):19.
Curry LA, Krumholtz HM, Okatherine A, Plano Clark VL, Charlyn E, Bradley EH. Mixed methods in biomedical and health services research. Circ Cardiovasc Qual results. 2013;6(1):119–23.
Persad G, Lynch HF, Largent E. Differential payments to study participants in the same study: an ethical analysis. J Medical Ethics. 2019;45(5):318–22.
ICC/Esomer. ICC/ESOMAR International Code of Markets, Public Opinion, Social Research and Data Analysis 2016. Available from https://www.esomar.org/what-we-do/code-guidelines.
Pallinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed-method induction studies. Management Policy Mental Health. 2015;42(5):533–44.
Norwell LS, Norris JM, White DE, Mools, NJ. thematic analysis. Int J Qual method. 2017;16(1):160940691773384.
Onwegbuzy AJ, Bustamante RM, Nelson JA. Mixed studies as a tool for developing quantitative instruments. J Mixed Res. 2009;4(1):56–78.
Turner SF, Cardinal LB, Burton RM. Mixed methods study design. Organ examination method. 2016;20(2):243–67.
Komiya T, Chaaya G, Deshotels L, Wang A. Differences in environments supporting research and clinical practice in the US and Japan. J Thorac Dis. 2020;12(7):3804–8.
Kerr KM, Bibeau F, Thunissen E, Botling J, Ryska A, Wolf J et al. Evolution of non-small cell lung cancer biomarker testing in Europe. lung cancer. 2021; 154:161–75.
Salvatore D, Santoro M, Schlumberger M. Importance and therapeutic implications of the RET gene in thyroid cancer. Nat Rev Endocrine. 2021;17(5):296–306.
Hiroshi Bando: Current situation and problems faced in providing precision medicine in Japan and Europe. Potential for current cancer. 2017;41(3):166–75.
Madrigal E. Going Remote: Maintaining Normalcy in Pathology Labs During the COVID-19 Pandemic. cancer cytopath. 2020; 128(5):321–2.
Malapelle U, De Luca C, Iaccarino A, Pepe F, Pisapia P, Russo M, et al. Prediction of molecular pathology in the era of COVID-19. J Kling Pasol. 2021;74(4):234–7.
Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicin C, etc. Global Impact of the COVID-19 Pandemic on Cytopathology Practice: Findings from an International Survey of Laboratories in 23 Countries. cancer cytopath. 2020; 128(12):885–94.
Hofman P, Ilie M, Chamorey E, Brest P, Schiappa R, nakache V, et al. Clinical and molecular practice of a European thoracic pathology laboratory under the novel coronavirus disease (COVID-19) pandemic. past and near future. Esmo open. 2021;6(1):100024.
Quality Assurance Initiative Pathology (QuIP GmbH). QuIP German Society of Pathologists and German Federal Association of Pathologists 2022[Availablehere:https://wwwquipeu/de_DE/[Availablefrom:https://wwwquipeu/de_DE/[こちらから入手可能:https://wwwquipeu/de_DE/。[Availablefrom:https://wwwquipeu/de_DE/
Siemanowski J, Heydt C, Merkelbach-Bruse S. Prediction of the molecular pathology of lung cancer in Germany with a focus on gene fusion testing: methods and quality assurance. cancer cytopath. 2020; 128(9):611–21.
Swing SR. ACGME Outcome Project: Retrospective and Prospective. Med Teach. 2007;29(7):648–54.
Royal Canadian Association of Physicians and Surgeons. CanMEDS: Better Standards, Better Doctors, Better Care Ottawa 2015[Availablefrom:https://wwwroyalcollegeca/rcsite/canmeds/canmeds-framework-e[Availablefrom:https://wwwroyalcollegeca/rcsite/canmeds/canmeds-framework-e[以下から入手可能:https://wwwroyalcollegeca/rcsite/canmeds/canmeds-framework-e。[Availablefrom:https://wwwroyalcollegeca/rcsite/canmeds/canmeds-framework-e
Djurbegovic B, Guyat GH. Advances in Evidence-Based Medicine: A Quarter Century. lancet. 2017;390(10092):415–23.
Desy JR, Reed DA, Wolanskyj AP. Milestones and Millennials: The perfect combination of competency-based medical education and her Gen Y learning preferences. Mayo Clinic Dr. 2017;92(2):243–50.